Amicus Therapeutics Stock Filter Stocks by Fundamentals
| FOLD Stock | USD 6.05 0.09 1.51% |
Fundamental analysis of Amicus Therapeutics allows traders to better anticipate movements in Amicus Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Amicus | Shares Owned by Institutions | Build AI portfolio with Amicus Stock |
Amicus Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Amicus Therapeutics from analyzing Amicus Therapeutics' financial statements. These drivers represent accounts that assess Amicus Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Amicus Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 6.0B | 3.1B | 3.5B | 4.2B | 2.9B | 3.0B | |
| Enterprise Value | 6.3B | 3.3B | 3.8B | 4.4B | 3.1B | 3.3B |
Amicus Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Amicus Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Amicus Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Amicus Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Amicus Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Amicus Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Amicus Therapeutics' value.| Shares | Geode Capital Management, Llc | 2025-03-31 | 6.8 M | Bank Of America Corp | 2025-03-31 | 5.6 M | Jpmorgan Chase & Co | 2025-03-31 | 4.9 M | Vestal Point Capital Lp | 2025-03-31 | 4.3 M | American Century Companies Inc | 2025-03-31 | 3.9 M | Nuveen Asset Management, Llc | 2024-12-31 | 3.8 M | Assenagon Asset Management Sa | 2025-06-30 | 3.5 M | Nuveen, Llc | 2025-03-31 | 3.5 M | Northern Trust Corp | 2025-03-31 | 3.4 M | Wellington Management Company Llp | 2025-03-31 | 29.2 M | Vanguard Group Inc | 2025-03-31 | 29.1 M |
Amicus Fundamentals
| Return On Equity | -0.18 | ||||
| Return On Asset | 0.0395 | ||||
| Profit Margin | (0.05) % | ||||
| Operating Margin | (0.06) % | ||||
| Current Valuation | 2.03 B | ||||
| Shares Outstanding | 307.93 M | ||||
| Shares Owned By Insiders | 0.71 % | ||||
| Shares Owned By Institutions | 99.29 % | ||||
| Number Of Shares Shorted | 21.26 M | ||||
| Price To Earning | (9.18) X | ||||
| Price To Book | 9.48 X | ||||
| Price To Sales | 3.43 X | ||||
| Revenue | 528.29 M | ||||
| Gross Profit | 492.07 M | ||||
| EBITDA | 29.39 M | ||||
| Net Income | (56.11 M) | ||||
| Cash And Equivalents | 386.84 M | ||||
| Cash Per Share | 1.38 X | ||||
| Total Debt | 443.64 M | ||||
| Debt To Equity | 2.60 % | ||||
| Current Ratio | 3.02 X | ||||
| Book Value Per Share | 0.63 X | ||||
| Cash Flow From Operations | (33.89 M) | ||||
| Short Ratio | 4.70 X | ||||
| Earnings Per Share | (0.09) X | ||||
| Price To Earnings To Growth | (0.18) X | ||||
| Target Price | 15.82 | ||||
| Number Of Employees | 499 | ||||
| Beta | 0.53 | ||||
| Market Capitalization | 1.86 B | ||||
| Total Asset | 785.03 M | ||||
| Retained Earnings | (2.74 B) | ||||
| Working Capital | 356.03 M | ||||
| Current Asset | 216.6 M | ||||
| Current Liabilities | 73.62 M | ||||
| Net Asset | 785.03 M |
About Amicus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Amicus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amicus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amicus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:Check out Amicus Therapeutics Piotroski F Score and Amicus Therapeutics Altman Z Score analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.09) | Revenue Per Share | Quarterly Revenue Growth 0.134 | Return On Assets | Return On Equity |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.